PriceTargets.com logo

NASDAQ:QDEL - Quidel Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $245.60
  • Forecasted Upside: 62.33 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$151.30 As of 03/5/2021 01:00 AM ET
▲ +3.31 (2.24%)
1 month | 3 months | 12 months
Get New Quidel Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QDEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QDEL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$245.60
▲ +62.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Quidel in the last 3 months. The average price target is $245.60, with a high forecast of $363.00 and a low forecast of $90.00. The average price target represents a 62.33% upside from the last price of $151.30.
Hold
The current consensus among 5 polled investment analysts is to hold stock in Quidel. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/10/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021Raymond JamesLower Price TargetOutperform$250.00 ➝ $245.00Medium
i
2/19/2021JPMorgan Chase & Co.Lower Price TargetUnderweight$175.00 ➝ $170.00High
i
1/22/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$250.00High
i
10/30/2020JPMorgan Chase & Co.Boost Price TargetUnderweight$185.00 ➝ $190.00Medium
i
7/31/2020Craig HallumBoost Price TargetPositive ➝ Buy$306.00 ➝ $363.00Medium
i
7/31/2020Piper SandlerBoost Price TargetOverweight$250.00 ➝ $360.00High
i
7/8/2020Piper SandlerBoost Price TargetOverweight$168.00 ➝ $250.00Medium
i
7/7/2020Craig HallumBoost Price TargetBuy$170.00 ➝ $306.00Medium
i
5/12/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$120.00 ➝ $158.00High
i
5/7/2020Craig HallumBoost Price TargetMarket Perform ➝ Buy$125.00 ➝ $170.00Medium
i
3/26/2020BarclaysReiterated RatingOverweight ➝ Equal Weight$90.00High
i
3/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
i
2/13/2020Raymond JamesBoost Price TargetStrong-Buy$70.00 ➝ $92.00Medium
i
11/17/2019Canaccord GenuityReiterated RatingBuy$70.00 ➝ $75.00Low
i
8/29/2019Craig HallumUpgradeHold ➝ Buy$63.00 ➝ $75.00High
i
7/1/2019Canaccord GenuityReiterated RatingBuy$70.00Low
i
4/15/2019Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$72.00 ➝ $74.00Medium
i
Rating by John Hsu at Raymond James
3/18/2019BarclaysBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
i
2/15/2019BarclaysReiterated RatingBuy$74.00Low
i
2/14/2019Craig HallumBoost Price TargetHold$51.00 ➝ $63.00High
i
Rating by Alexander Nowak at Craig Hallum
12/11/2018Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$80.00 ➝ $70.00Medium
i
Rating by John Hsu at Raymond James
12/11/2018Canaccord GenuityDowngradeBuyHigh
i
12/10/2018Craig HallumDowngradeBuy ➝ Hold$80.00 ➝ $51.00High
i
12/10/2018BarclaysLower Price TargetOverweight ➝ Overweight$85.00 ➝ $77.00High
i
10/23/2018Raymond JamesReiterated RatingStrong-Buy ➝ Strong-Buy$80.00Medium
i
9/10/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$78.00 ➝ $80.00Low
i
8/14/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$75.00 ➝ $78.00Low
i
8/8/2018Craig HallumBoost Price TargetBuy$64.00 ➝ $80.00High
i
Rating by Alexander Nowak at Craig Hallum
8/8/2018Piper Jaffray CompaniesReiterated RatingIn-Line ➝ Overweight$74.00High
i
8/6/2018BarclaysBoost Price TargetOverweight ➝ Overweight$65.00 ➝ $78.00Medium
i
5/10/2018BarclaysReiterated RatingBuy$65.00High
i
4/13/2018William BlairReiterated RatingBuyLow
i
4/5/2018Canaccord GenuityBoost Price TargetBuy$55.00 ➝ $64.00Low
i
4/4/2018Piper Jaffray CompaniesReiterated RatingBuy$63.00Low
i
4/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$60.00 ➝ $63.00Low
i
3/26/2018Craig HallumInitiated CoverageBuy$62.00Low
i
3/8/2018Raymond JamesUpgradeOutperform ➝ Strong-Buy$55.00 ➝ $47.00Medium
i
3/8/2018UBS GroupUpgradeOutperform ➝ Strong-BuyHigh
i
1/24/2018Piper Jaffray CompaniesReiterated RatingBuy$60.00Low
i
1/22/2018BarclaysBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $60.00High
i
1/4/2018CL KingUpgradeNeutral ➝ Buy$52.00High
i
12/21/2017Canaccord GenuityReiterated RatingBuy$48.00 ➝ $52.00Medium
i
12/14/2017Piper Jaffray CompaniesReiterated RatingBuy$50.00Low
i
11/3/2017Piper Jaffray CompaniesReiterated RatingBuy$50.00N/A
i
11/2/2017BarclaysBoost Price TargetOverweight$45.00 ➝ $49.00N/A
i
10/25/2017Canaccord GenuityReiterated RatingBuy$48.00N/A
i
9/19/2017Canaccord GenuityReiterated RatingBuy$42.00 ➝ $48.00High
i
9/19/2017BarclaysReiterated RatingBuy$39.00 ➝ $45.00High
i
9/19/2017Raymond JamesReiterated RatingBuy$41.00 ➝ $47.00High
i
9/19/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$35.00 ➝ $50.00High
i
7/27/2017Raymond JamesBoost Price TargetOutperform$36.00 ➝ $41.00High
i
7/27/2017BarclaysBoost Price TargetOverweight$36.00 ➝ $39.00High
i
7/18/2017William BlairUpgradeMarket Perform ➝ OutperformHigh
i
7/18/2017Canaccord GenuityUpgradeHold ➝ BuyHigh
i
Rating by Mark Massaro at Canaccord Genuity
5/19/2017Canaccord GenuityReiterated RatingHold$24.50 ➝ $25.00Low
i
Rating by Mark Massaro at Canaccord Genuity
4/26/2017BarclaysBoost Price TargetOverweight$26.00 ➝ $27.00Low
i
4/25/2017Canaccord GenuityReiterated RatingHold$24.00 ➝ $24.50High
i
Rating by Mark Massaro at Canaccord Genuity
2/17/2017CL KingInitiated CoverageNeutralN/A
i
1/23/2017Canaccord GenuityReiterated RatingHold$22.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
12/16/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$22.00N/A
i
10/27/2016Canaccord GenuitySet Price TargetHold$22.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
7/29/2016Canaccord GenuityReiterated RatingHold$22.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
6/13/2016Raymond JamesUpgradeMarket Perform ➝ Outperform$21.50N/A
i
4/28/2016Canaccord GenuityReiterated RatingHoldN/A
i
Rating by Mark Massaro at Canaccord Genuity
3/21/2016Canaccord GenuityReiterated RatingHold$17.00 ➝ $18.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
(Data available from 3/7/2016 forward)
Quidel logo
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $151.30
$138.29
$152.76

50 Day Range

MA: $210.36
$147.99
$254.00

52 Week Range

Now: $151.30
$73.01
$306.72

Volume

874,697 shs

Average Volume

974,801 shs

Market Capitalization

$6.40 billion

P/E Ratio

17.76

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Quidel?

The following sell-side analysts have issued reports on Quidel in the last twelve months: Barclays PLC, Craig Hallum, JPMorgan Chase & Co., Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for QDEL.

What is the current price target for Quidel?

5 Wall Street analysts have set twelve-month price targets for Quidel in the last year. Their average twelve-month price target is $245.60, suggesting a possible upside of 62.3%. Craig Hallum has the highest price target set, predicting QDEL will reach $363.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $90.00 for Quidel in the next year.
View the latest price targets for QDEL.

What is the current consensus analyst rating for Quidel?

Quidel currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in QDEL, but not buy more shares or sell existing shares.
View the latest ratings for QDEL.

What other companies compete with Quidel?

Other companies that are similar to Quidel include Align Technology, West Pharmaceutical Services, The Cooper Companies, DENTSPLY SIRONA, Haemonetics, ICU Medical, Neogen, STAAR Surgical, Merit Medical Systems, Atrion, Cerus, Meridian Bioscience, OraSure Technologies, Antares Pharma and Anika Therapeutics.

How do I contact Quidel's investor relations team?

Quidel's physical mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company's listed phone number is 858-552-1100 and its investor relations email address is [email protected] The official website for Quidel is www.quidel.com.